Prevention of catheter-associated gram-negative bacilluria with norfloxacin by selective decontamination of the bowel and high urinary concentration.

Abstract

Oral norfloxacin prevented Gram-negative bacilluria in female patients with hip fractures, who needed medium-term transurethral catheterization. This was shown in a placebo-controlled double-blind study of 34 patients. Seventeen of these received a suspension containing 200 mg norfloxacin and 500 mg amphotericin B, twice daily. In the placebo group, six cases of Gram-negative bacilluria had occurred by day 7, as compared with no cases during a median time of catheterization of 23 days in the group on medication. Bacteriuria, either by Gram-positive cocci or by Gram-negative bacilli, was observed in 50% of patients on placebo by day 7; in the treatment group this was the case by day 17 (P less than 0.001). Subsequent bacteriuria with Gram-positive cocci was eliminated by nitrofurantoin (50 mg qid) within four days. Norfloxacin is very suitable for the prevention of Gram-negative bacilluria, because it decontaminates Gram-negative bacilli from the bowel, reaches high concentrations in urine and rarely produces resistant variants.

• Authors: E J Vollaard, H A Clasener, J V Zambon, H J Joosten, A J van Griethuysen
• Journal: The Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 23 Issue 6 Pg. 915-22 (Jun 1989) ISSN: 0305-7453 [Print] England
• PMID: 2668253 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Amphotericin B
• Norfloxacin

Topics

• Aged
• Aged, 80 and over
• Amphotericin B (therapeutic use)
• Bacteriuria (prevention & control)
• Candida albicans
• Digestive System (microbiology)
• Feces (microbiology)
• Female
• Gram-Negative Bacteria
• Hip Fractures (complications, microbiology)
• Humans
• Norfloxacin (therapeutic use, urine)
• Urinary Catheterization (adverse effects)